VDYNE

VDYNE Secures FDA Approval to Launch TRIVITA1 Pivotal IDE Trial for Its Transcatheter Tricuspid Valve Replacement System

VDYNE Secures FDA IDE Approval to Advance Pivotal TRIVITA1 Trial for Transcatheter Tricuspid Valve Replacement System VDYNE, Inc., a privately held medical device innovator focused on next-generation transcatheter valve therapies, has achieved a major regulatory milestone with the approval of…

Read MoreVDYNE Secures FDA Approval to Launch TRIVITA1 Pivotal IDE Trial for Its Transcatheter Tricuspid Valve Replacement System
SCP

SCP Health Broadens Performance Edge Model to Enhance Hospital-Based Care

SCP Health Expands Performance Edge Model to Strengthen Hospital-Based Care Hospitals across the United States are navigating an increasingly complex healthcare environment marked by workforce shortages, financial pressures, and rising administrative demands. In response to these challenges, SCP Health, a…

Read MoreSCP Health Broadens Performance Edge Model to Enhance Hospital-Based Care
RefleXion

RefleXion Gains Expanded Medicare Coverage for SCINTIX Cancer Therapy

RefleXion Expands Medicare Reimbursement for SCINTIX Therapy Across Majority of U.S. Regions RefleXion Medical has announced a significant advancement in expanding access to its innovative SCINTIX® autonomous radiotherapy, as another Medicare Administrative Contractor (MAC), Noridian Healthcare Solutions, LLC, has approved…

Read MoreRefleXion Gains Expanded Medicare Coverage for SCINTIX Cancer Therapy
Alpha

Alpha Cognition Secures U.S. Patent for ALPHA-1062 Targeting Traumatic Brain Injury Treatment

Alpha Cognition Secures U.S. Patent for ALPHA-1062 in Traumatic Brain Injury, Expanding Pipeline Potential Alpha Cognition Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, has announced a significant milestone in its intellectual property strategy. The…

Read MoreAlpha Cognition Secures U.S. Patent for ALPHA-1062 Targeting Traumatic Brain Injury Treatment
Alto

Alto Neuroscience Announces Phase 2 Topline Results for ALTO-101 and Pipeline Progress

Alto Neuroscience Shares Phase 2 Results for ALTO-101 and Refocuses Pipeline Strategy Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company dedicated to developing precision medicines for neuropsychiatric disorders, has released topline findings from its Phase 2 proof-of-concept (POC) study evaluating ALTO-101.…

Read MoreAlto Neuroscience Announces Phase 2 Topline Results for ALTO-101 and Pipeline Progress
Premier

Premier Radiology Services Expands Capabilities with Acquisition of Global Imaging Solutions

Premier Radiology Services Acquires Global Imaging Solutions to Expand Teleradiology and Subspecialty Expertise Premier Radiology Services (Premier) has announced the acquisition of Global Imaging Solutions (GLOBIS), a well-established teleradiology provider known for delivering subspecialty imaging interpretations to outpatient imaging centers…

Read MorePremier Radiology Services Expands Capabilities with Acquisition of Global Imaging Solutions
FORE

FORE Biotherapeutics’ Plixorafenib Granted Breakthrough Therapy Designation

FORE Biotherapeutics Secures Breakthrough Therapy Designation for Plixorafenib in High-Grade Glioma FORE Biotherapeutics, a clinical-stage company focused on developing precision oncology therapies, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its…

Read MoreFORE Biotherapeutics’ Plixorafenib Granted Breakthrough Therapy Designation
Frontier

Frontier Medicines Signs Exclusive Licensing Deal with LG Chem for First-in-Class p53 Y220C Activator FMC-220

Frontier Medicines and LG Chem Forge Strategic Global Partnership for First-in-Class p53 Y220C Activator FMC-220 Frontier Medicines Corporation has entered into a landmark exclusive licensing agreement with LG Chem, Ltd. for its novel oncology candidate FMC-220, a first-in-class covalent activator…

Read MoreFrontier Medicines Signs Exclusive Licensing Deal with LG Chem for First-in-Class p53 Y220C Activator FMC-220